Trial Profile
An Open-Label, Multi-center, Expanded Access Protocol of Blinatumomab for the Treatment of Pediatric and Adolescent Subjects With Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Expanded access
- Acronyms RIALTO
- Sponsors Amgen
- 24 Feb 2023 Results of pooled analysis (n=683) assessing the association between bBMB% and treatment outcomes in relapsed/refractory (R/R) B-acute lymphoblastic leukemia from 5 trials (NCT01209286, NCT01466179, NCT01471782, NCT02013167, NCT02187354), published in the Cancer.
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 30 Nov 2020 According to an Amgen media release, data from this study will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition.